A Clinical Study of the Efficacy and Safety of Disitamab Vedotin in Combination With Radiotherapy for the Adjuvant Treatment of HER2 Overexpressing UTUC Patients With High Risk Factors for Recurrence After Radical Surgery

NCT06210490 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Upper Urinary Tract Urothelial Carcinoma

Interventions

DRUG: Disitamab Vedotin
RADIATION: Radiotherapy
OTHER: Standard of Care

Sponsor

Peking University First Hospital